Vaccine developer Pfizer announces that lab studies have concluded that the joint Pfizer–BioNTech vaccine remains effective against mutation variants of the SARS-CoV-2 virus, including Variant of Concern 202012-01 and the 501.V2 variant.
Vaccine developer Pfizer announces lab studies have concluded that the joint Pfizer–BioNTech vaccine remains effective against mutation variants of the SARS-CoV-2 virus, including Variant of Concern 202012-01 and the 501.V2 variant.
Vaccine developer Pfizer announces thatlab studies have concluded that the joint Pfizer–BioNTech vaccine remains effective against mutation variants of the SARS-CoV-2 virus, including Variant of Concern 202012-01 and the 501.V2 variant.
